Strategy Inc., the largest corporate Bitcoin holder, paused Bitcoin purchases for a second week, maintaining its holdings at 843,775 BTC. Instead of selling Bitcoin, the company raised $263.5 million through stock sales to increase cash reserves to $3.2 billion, aiming to cover dividends and debt interest. This shift from buying to preserving Bitcoin reflects caution amid recent price declines and an expected $8.32 billion unrealized loss on its digital assets. The move signals a strategic pivot from accumulation to balance-sheet defense, potentially impacting investor perception and dividend sustainability if Bitcoin prices stay low.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
Shares of Zhengye Biotechnology surged over 1047% to regain Nasdaq compliance after a minimum bid price warning. Advanced Biomed and Axe Compute also saw notable gains following a reverse stock split and Russell Microcap Index inclusion, respectively...
